NRSN (NeuroSense Therapeutics) Total Operating Expense: $11.09 Mil (TTM As of Dec. 2025)


NRSN NeuroSense Therapeutics Ltd NRSN
29 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Total Operating Expense?

NeuroSense Therapeutics NRSN -0.21% 29 Total Operating Expense is $11.09 Mil as of Dec. 2025. GuruFocus rates NRSN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

NeuroSense Therapeutics's Total Operating Expense for the six months ended in Dec. 2025 was $6.39 Mil. NeuroSense Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $11.09 Mil.

NeuroSense Therapeutics Total Operating Expense Related Terms

NeuroSense Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics Total Operating Expense Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 5.59 10.55 12.05 9.90 11.09

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.69 6.02 3.88 4.69 6.39
NRSN
29GF Score
NeuroSense Therapeutics Ltd NRSN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $11.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $11.09 Mil mean?
NeuroSense Therapeutics (NRSN) has a Total Operating Expense of $11.09 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on NeuroSense Therapeutics and its competitors.
Is NeuroSense Therapeutics' Total Operating Expense too high?
NeuroSense Therapeutics' current Total Operating Expense is $11.09 Mil. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' Total Operating Expense compare to SNTI and LSTA?
NeuroSense Therapeutics' Total Operating Expense of $11.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current Total Operating Expense is $11.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSN) has a current Total Operating Expense of $11.09 Mil. The current Total Operating Expense is $11.09 Mil. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSN), the current Total Operating Expense is $11.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges H1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price